FGFR3 (K650Q)
Sign in to save this workspaceFGFR3 · Variant type: point · HGVS: p.K650Q
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Futibatinib | 98.7% | 1.4% | 98.48 |
| 2 | Erdafitinib | 98.5% | 1.5% | 95.71 |
| 3 | Infigratinib | 97.8% | 2.1% | 98.24 |
| 4 | Nintedanib | 96.6% | 3.4% | 90.23 |
| 5 | Pemigatinib | 96.4% | 3.6% | 98.23 |
| 6 | Selpercatinib | 95.8% | 4.2% | 96.72 |
| 7 | Alpelisib | 95.0% | 5.0% | 97.22 |
| 8 | Brigatinib | 94.4% | 5.6% | 82.96 |
| 9 | Vandetanib | 91.9% | 8.1% | 95.74 |
| 10 | Ponatinib | 86.3% | 13.7% | 78.23 |
| 11 | Tenalisib | 82.4% | 17.6% | 97.98 |
| 12 | Canertinib | 82.1% | 17.9% | 96.49 |
| 13 | Sunitinib | 81.1% | 18.9% | 91.73 |
| 14 | Axitinib | 80.1% | 19.9% | 93.23 |
| 15 | Pralsetinib | 73.6% | 26.4% | 93.43 |
| 16 | Erlotinib | 73.5% | 26.5% | 99.75 |
| 17 | Pazopanib | 73.0% | 27.0% | 97.49 |
| 18 | Deucravacitinib | 72.9% | 27.1% | 98.99 |
| 19 | Regorafenib | 68.2% | 31.8% | 95.99 |
| 20 | Lenvatinib | 64.6% | 35.4% | 97.74 |
| 21 | Ripretinib | 61.7% | 38.3% | 92.95 |
| 22 | Fostamatinib | 59.2% | 40.8% | 96.74 |
| 23 | Repotrectinib | 54.1% | 45.9% | 84.21 |
| 24 | Pacritinib | 52.9% | 47.1% | 88.64 |
| 25 | Tivozanib | 52.5% | 47.5% | 92.42 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Futibatinib | 98.7% | 99.0% | -0.4% |
| Erdafitinib | 98.5% | 99.1% | -0.5% |
| Infigratinib | 97.8% | 98.6% | -0.8% |
| Nintedanib | 96.6% | 91.0% | +5.7% |
| Pemigatinib | 96.4% | 99.4% | -2.9% |
| Selpercatinib | 95.8% | 86.6% | +9.2% |
| Alpelisib | 95.0% | 98.6% | -3.6% |
| Brigatinib | 94.4% | 74.6% | +19.8% |
| Vandetanib | 91.9% | — | — |
| Ponatinib | 86.3% | 96.7% | -10.4% |
| Tenalisib | 82.4% | 98.0% | -15.6% |
| Canertinib | 82.1% | — | — |
| Sunitinib | 81.1% | 66.2% | +14.9% |
| Axitinib | 80.1% | 93.1% | -13.0% |
| Pralsetinib | 73.6% | 90.6% | -17.0% |
| Erlotinib | 73.5% | — | — |
| Pazopanib | 73.0% | 78.7% | -5.7% |
| Deucravacitinib | 72.9% | 93.3% | -20.4% |
| Regorafenib | 68.2% | — | — |
| Lenvatinib | 64.6% | 79.9% | -15.3% |
| Ripretinib | 61.7% | — | — |
| Fostamatinib | 59.2% | — | — |
| Repotrectinib | 54.1% | — | — |
| Pacritinib | 52.9% | 70.5% | -17.6% |
| Tivozanib | 52.5% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_urinary_tract | Biliary Tract | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.9ms